This year we announce “Today, together. Improving access”: a global campaign dedicated to the CML patients to address our needs such as:
- Improving access… to quality treatment
- Improving access… to correct monitoring
- Improving access… to the quality of life
- Improving access… to research and science
- Improving access… to patient education and advocacy
- Improving access… to Health Care Professionals & patient communication
- The entire Chronic Myeloid Leukemia community comes together every 22nd September to raise awareness on this rare haematological disease that represents over 20% of all leukemia in adults and the needs of patients around the world.
- Chronic Myeloid Leukemia patients have very different access to effective and safe treatment’s worldwide but the whole CML community call to have improved access to treatment, monitoring, quality of life, research and science, patient education and advocacy and HCP and patient communication.
Today, together Henzo Kenya, in conjunction with other like organizations under the umbrella of Kenya (KENCO) and the CML Advocates Network are fighting for access to treatment, especially second line treatment and affordable diagnostics and monitoring. On one day, 22 September 2018, one community across the globe stands together to raise awareness about one life changing reality – living with chronic myeloid leukemia (CML). On World CML Day simultaneous events, publications and meetings are taking place on all continents. All activities are being coordinated by the CML Advocates Network, a patient-run network comprised of 115 patient advocacy groups in 86 countries.
“Advances in treatment and care have transformed CML into a disease where patients, if treated effectively, have the chance to live a normal and long life. “However, there are still huge challenges for patients with CML, which also vary from region to region”, said Jan Geissler, CML patient and co-founder of the CML Advocates Network. These challenges, such as access to high quality therapies and diagnostics, treatment according to expert recommendations, adherence to therapy, effective side effect management, and development of a cure can only be tackled in partnership between patients, healthcare providers and researchers. “Especially here in Kenya, our key concerns are that patients can’t get access to regular monitoring due to cost barrier, We therefore Request the National Insurer, NHIF to pay for monitoring and treatment for all CML patients”. said Elo Mapelu, Chairman, Henzo Kenya.